Standout Papers

Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia 2022 2026 2023 2024115
  1. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
    Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology

Immediate Impact

1 from Science/Nature 54 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
2 intermediate papers

Works of Terrence Bradley being referenced

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
2022
Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
2022

Author Peers

Author Last Decade Papers Cites
Terrence Bradley 335 94 264 48 462
Prapti A. Patel 298 87 230 57 490
Kaoru Nagata 286 89 177 54 477
Juergen Krauter 327 89 212 20 415
Margaret M. Showel 333 66 165 29 466
Clifton C. Mo 230 69 206 44 463
Aditi Shastri 305 126 168 55 520
Lynn Savoie 294 141 233 25 510
Barbara Scappini 388 238 185 42 566
Marion Eveillard 242 72 170 58 420
Elliot Stieglitz 269 124 227 53 496

All Works

Loading papers...

Rankless by CCL
2026